QXL138AM-001: Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Condition: Solid Tumors or Multiple Myeloma
Sponsor: Nammi Therapeutics Inc
Full Title
Protocol QXL138AM-001: A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma
Study Treatment
QXL138AM is interferon alpha 2 (IFNα2) masked immunocytokine (MIC) fused to antibody targeting CD138
Eligibility/Info
Solid tumors: Metastatic ovarian, pancreatic, urothelial, renal, hepatocellular, gastrointestinal (GI), lung, prostate, or breast cancer that has continued to grow after standard systemic therapies.
Multiple Myeloma: Multiple myeloma that has continued to grow after treatment with at least 3 lines of therapy that included an anti-CD38 antibody, a proteasome inhibitor, and an immunomodulating agent.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
